Crosstalk between the estrogen receptor (ER) pathway and the PI3K or ERK/MAPK pathway is thought to be involved in the resistance to trastuzumab-containing chemotherapy in HER2+/HR+ breast cancer [8]. Here, ERBB2 is linked to breast cancer.